↓ Skip to main content

Prognostic value of ERBB4 expression in patients with triple negative breast cancer

Overview of attention for article published in BMC Cancer, February 2016
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (56th percentile)
  • Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

patent
1 patent

Citations

dimensions_citation
36 Dimensions

Readers on

mendeley
47 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Prognostic value of ERBB4 expression in patients with triple negative breast cancer
Published in
BMC Cancer, February 2016
DOI 10.1186/s12885-016-2195-3
Pubmed ID
Authors

Ji-Yeon Kim, Hae Hyun Jung, In-Gu Do, SooYoun Bae, Se Kyung Lee, Seok Won Kim, Jeong Eon Lee, Seok Jin Nam, Jin Seok Ahn, Yeon Hee Park, Young-Hyuck Im

Abstract

Triple-negative breast cancer (TNBC) is known for aggressive biologic features and poor prognosis. Epidermal growth factor receptor (EGFR) overexpression in TNBC indicates poor prognosis. However, there is no previous study of the relationship between expression of the entire human epidermal growth factor receptor (HER) family genes and patient prognosis in TNBC. Accordingly, we investigated the expression profiles of HER family genes in patients with TNBC to determine the prognostic value and clinical implications of HER family expression. We used the nCounter expression assay (NanoString®) to measure the expression of EGFR, erb-B2 receptor tyrosine kinase 2 (ERBB2), ERBB3, ERBB4, and estrogen receptor 1 (ESR1) genes using mRNA extracted from paraffin-embedded tumor tissues from 203 patients diagnosed with TNBC. Our data were validated using a separate cohort of 84 TNBC patients. A total of 203 TNBC patients who received adjuvant chemotherapy after curative surgery from 2000 to 2004 formed the training set. The 84 TNBC patients in the validation consort were selected from breast cancer patients who received curative surgery since 2005 to 2010. Analysis of the expression profiles of the HER family genes in TNBC tissue specimens revealed that increased expression of ERBB4 was associated with poor prognosis according to survival analysis (5-year distant relapse free survival [5Y DRFS], low vs. high expression [cut-off: median]: 90.1 % vs. 80.2 %; p = 0.022). This trend was also observed in the validation set of TNBC patients (5Y DRFS, low vs. high: 69.4 % vs. 44.7 %; p = 0.053). In a multivariate Cox regression model, ERBB4 expression was identified as a indicator of long-term prognosis in patients with TNBC. The expression profile of ERBB4, a member of the HER family, might serve as a prognostic marker in patients with TNBC.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 47 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 47 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 9 19%
Student > Bachelor 7 15%
Student > Doctoral Student 4 9%
Student > Master 4 9%
Researcher 4 9%
Other 8 17%
Unknown 11 23%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 14 30%
Medicine and Dentistry 8 17%
Agricultural and Biological Sciences 5 11%
Psychology 2 4%
Pharmacology, Toxicology and Pharmaceutical Science 1 2%
Other 5 11%
Unknown 12 26%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 August 2018.
All research outputs
#7,474,859
of 22,851,489 outputs
Outputs from BMC Cancer
#2,066
of 8,314 outputs
Outputs of similar age
#105,654
of 298,746 outputs
Outputs of similar age from BMC Cancer
#44
of 185 outputs
Altmetric has tracked 22,851,489 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,314 research outputs from this source. They receive a mean Attention Score of 4.3. This one has gotten more attention than average, scoring higher than 68% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 298,746 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.
We're also able to compare this research output to 185 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.